• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

    6/16/25 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CRL alert in real time by email

    A solution for laboratories seeking to reduce single-use plastic waste

    Charles River Laboratories International, Inc. (NYSE:CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River's Endosafe® bacterial endotoxin testing (BET) cartridge technology an avenue to responsibly recycle single-use plastic cartridges used specifically for routine water testing. The cartridge recycling program reaffirms Charles River's ongoing commitment to minimize the Company's environmental footprint and offer a service to assist clients in meeting their sustainability goals.

    "We recognize that a typical quality control microbiology laboratory generates volumes of plastic waste during standard testing and monitoring," said Matthew Hewitt, PhD, Vice President and Chief Technical Officer, Manufacturing Business Division, Charles River. "This waste includes tips, plastic-based packaging, and consumables. In many cases, these are discarded as biohazardous waste, even when they pose minimal biological risk. This includes materials used in water testing. Our cartridge recycling program works to address this challenge by offering a path to recycle these cartridges, reduce waste, and ultimately support labs seeking to align their testing workflows and supply chains with sustainability goals."

    More than 20 years ago, Charles River pioneered Endosafe Cartridge Technology, a microfluidic approach that reduced the amount of horseshoe crab-derived Limulus Amebocyte Lysate (LAL) required for each test by more than 95 percent. That work continued with the launch of Endosafe Trillium™, a recombinant cascade reagent (rCR), designed to meet global regulatory standards while supporting 3Rs initiatives. While cartridge-based testing already eliminates many sample preparation steps that rely on other single-use plastics, such as pipette tips and packaging, this new recycling program allows enrolled customers to return plastic cartridges used specifically for water testing and have them responsibly recycled.

    "The scientific community has made tremendous strides in advancing both innovation and sustainability," said Tom Szaky, Founder and CEO of TerraCycle. "Yet laboratory settings still face a significant challenge, as most single-use plastics, designed for precision, ultimately end up as waste. Through this partnership with Charles River, we're providing a practical way to recycle a high-volume lab consumable that would otherwise be destroyed. By integrating resource recovery into lab operations, we're making it easier for science to align with sustainability."

    This partnership with TerraCycle represents the next step in Charles River's broader sustainability efforts. The program will begin implementation in July, starting at Charles River's Microbial Solutions site in Charleston, South Carolina, where cartridges are manufactured. Cartridge customers in the United States and select European countries (Ireland, the United Kingdom, France, Spain, Germany, Belgium, the Netherlands, and Switzerland) can also enroll in the program beginning in July. Customers will receive a Zero Waste Box™ directly to their lab, collect cartridges used in the testing of water, which account for approximately 70 percent of global BETs, and return full boxes to TerraCycle. These will then be properly recycled and processed into raw materials that can be used to make new products, such as outdoor furniture, storage bins, park benches, and other durable goods. New boxes will be shipped automatically to support ongoing collection.

    The effort comes at a time when sustainability expectations are rising across the industry. The European Union continues to implement measures to reduce single-use plastics in alignment with its Circular Economy Action Plan. Globally, the World Economic Forum (WEF) and United Nations (UN) are supporting coordinated action to curb plastic pollution. By targeting single-use plastics that are low risk but high volume, this program helps labs take measurable action today, without revising existing testing workflows.

    About Charles River

    Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

    About TerraCycle

    TerraCycle is an international leader in innovative sustainability solutions, creating and operating first-of-their-kind platforms in recycling, recycled materials, and reuse. Across 21 countries, TerraCycle is on a mission to rethink waste and develop practical solutions for today's complex waste challenges. The company engages an expansive multi-stakeholder community across a wide range of accessible programs, from Fortune 500 companies to schools and individuals. To learn more about TerraCycle and join them on their journey to move the world from a linear economy to a circular one, please visit www.terracycle.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250616628100/en/

    Charles River Investor Contact:

    Todd Spencer

    Corporate Vice President,

    Investor Relations

    781.222.6455

    [email protected]



    Charles River Media Contact:

    Amy Cianciaruso

    Corporate Senior Vice President,

    Chief Communications Officer & Government Relations

    781.222.6168

    [email protected]

    Get the next $CRL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRL

    DatePrice TargetRatingAnalyst
    7/9/2025$200.00Neutral → Buy
    Citigroup
    5/23/2025$182.00Neutral → Buy
    Redburn Atlantic
    5/14/2025$179.00Hold → Buy
    TD Cowen
    5/8/2025$170.00In-line → Outperform
    Evercore ISI
    3/21/2025$190.00 → $170.00Buy → Neutral
    Goldman
    3/4/2025$155.00 → $175.00Sell → Neutral
    Citigroup
    3/3/2025$188.00Sell → Neutral
    Redburn Atlantic
    1/22/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $CRL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    2/21/25 4:41:25 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Corporate Executive VP & COO Girshick Birgit bought $249,250 worth of shares (1,514 units at $164.63), increasing direct ownership by 3% to 55,058 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    2/21/25 4:38:37 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Girshick Birgit gifted 350 shares and bought $248,298 worth of shares (1,322 units at $187.82), increasing direct ownership by 53% to 44,449 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    11/21/23 5:07:01 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    SEC Filings

    View All

    SEC Form 144 filed by Charles River Laboratories International Inc.

    144 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    8/18/25 5:16:06 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Charles River Laboratories International Inc.

    10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    8/6/25 9:07:31 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    8/6/25 7:08:41 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Corp Strategy & Develop Laplume Joseph W sold $126,080 worth of shares (800 units at $157.60), decreasing direct ownership by 3% to 24,116 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    8/20/25 4:45:35 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP, Corp Strategy & Develop Laplume Joseph W sold $60,016 worth of shares (400 units at $150.04), decreasing direct ownership by 2% to 24,916 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    8/8/25 4:18:55 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    New insider Mintz Mark claimed ownership of 6,350 shares (SEC Form 3)

    3 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    6/10/25 4:22:44 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Charles River upgraded by Citigroup with a new price target

    Citigroup upgraded Charles River from Neutral to Buy and set a new price target of $200.00

    7/9/25 8:08:21 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River upgraded by Redburn Atlantic with a new price target

    Redburn Atlantic upgraded Charles River from Neutral to Buy and set a new price target of $182.00

    5/23/25 8:13:14 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River upgraded by TD Cowen with a new price target

    TD Cowen upgraded Charles River from Hold to Buy and set a new price target of $179.00

    5/14/25 8:48:54 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Charles River Laboratories Announces Second-Quarter 2025 Results

    – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2025. For the quarter, revenue was $1,032.1 million, an increase of 0.6% from $1,026.1 million in the second quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.2%. Excluding this impact, revenue declined 0.5% on an organic basis. On a segment basis, an organic revenue decline in the Discovery and Safety Assessment (DSA) segment was partially offset by organic revenue growth

    8/6/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership

    Aim to Enhance Charles River Incubator and Accelerator Programs by adding crowdfunding features, aiding early-stage developers Charles River Laboratories International, Inc. (NYSE:CRL) and BioTech Social Inc. (BSI) today announced the exploration of a potential client-centric collaboration to enable Charles River Incubator (CIP) and Accelerator (CAP) Program participants to access the BioTech Funding Portal, an investment crowdfunding platform for life science companies. "We're thrilled to explore this collaboration that will open up an exciting new funding pathway to bridge innovation with the right audiences and investors. This dynamic approach would potentially streamline the deliver

    7/31/25 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

    Supporting fast-track production of therapeutic targeting ultra-rare neurodevelopmental disease Charles River Laboratories International, Inc. (NYSE:CRL) and Elly's Team, a parent-led foundation striving to find a cure for Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS), a rare genetic disorder, have announced a plasmid DNA contract development and manufacturing organization (CDMO) agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Elly's Team accessed established gene therapy CDMO capabilities and advisory services to manufacture critical starting materials for a Phase I clinical trial. Thi

    7/22/25 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Financials

    Live finance-specific insights

    View All

    Charles River Laboratories Announces Second-Quarter 2025 Results

    – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2025. For the quarter, revenue was $1,032.1 million, an increase of 0.6% from $1,026.1 million in the second quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.2%. Excluding this impact, revenue declined 0.5% on an organic basis. On a segment basis, an organic revenue decline in the Discovery and Safety Assessment (DSA) segment was partially offset by organic revenue growth

    8/6/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

    Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 6th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce

    7/15/25 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Announces First-Quarter 2025 Results

    – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the

    5/7/25 7:01:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Charles River Laboratories International Inc.

    SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    11/8/24 10:52:38 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    10/22/24 3:24:03 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by Charles River Laboratories International Inc. (Amendment)

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    2/13/24 5:01:02 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Leadership Updates

    Live Leadership Updates

    View All

    Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

    – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o

    5/7/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

    Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow

    7/24/24 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

    Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated

    1/24/24 4:30:00 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care